France· FR:66807418
GRANOCYTE 13 Millions UI/ml, poudre et solvant pour solution injectable/perfusion en seringue préremplie
A lenograstim product containing lénograstim, registered in France by CHUGAI PHARMA FRANCE, on the national reimbursement list. The same ATC class is registered in 8 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Lenograstim is registered in 8 of 19 countries.
Countries holding a registration under ATC L03AA10 (lenograstim), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 5 of them publish a price we can compare per daily dose
Lenograstim · ATC L03AA10
8 / 19 countries
- Belgiumprice
- Finlandprice
- Franceprice
- Germany
- Ireland
- Spainprice
- United Kingdom
- United Statesprice
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- LÉNOGRASTIM
- Manufacturer
- CHUGAI PHARMA FRANCE
- Country
- France (FR)
- ATC code
- L03AA10
- ATC class
- Lenograstim
- Defined daily dose
- 0.35 mg, P
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 2
1 priced- cip1334009349756771 flacon(s) de poudre en verre - 1 seringue(s) préremplie(s) de 1 ml de solvant en verre avec 2 aiguille(s)EUR 39.05
- cip1334009349757385 flacon(s) de poudre en verre - 5 seringue(s) préremplie(s) de 1 ml de solvant en verre avec 2 aiguille(s)
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Lenograstim in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomGranocyte 13million unit powder and solvent for solution for injection pre-filled syringesChugai Pharma UK Ltd
- FinlandGranocyteSanofi Oy
- Japanレノグラスチム(遺伝子組換え)中外製薬
- BelgiumGranocyte 13 1 10*6 IU/mlChugai Pharma France
- GermanyGranocyteChugai Pharma Germany Gmbh
- SpainGRANOCYTE 13 MILLONES DE UI POLVO Y DISOLVENTE PARA SOLUCION INYECTABLE O PERFUSIONItalfarmaco S.A.
- IrelandGRANOCYTE 13 million IU/mL, powder and solvent for solution for injection/infusion, in a pre-filled syringeChugai Pharma France
- SwedenGranocyte 34 miljoner IE/ml Pulver och vätska till injektions-/infusionsvätska, lösningSanofi AB
Authorised across Europe · EMA
The same active substance is authorised in 6 EEA countries. Names it is sold under:
- Belgium · Granocyte
- Germany · Granocyte
- United Kingdom (Northern Ireland) · Granocyte
- Ireland · Granocyte
- Luxembourg · Granocyte
- Sweden · Granocyte
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/715c5934-0e85-464d-86c0-d1c99e24cbcb GET /v1/drugs/715c5934-0e85-464d-86c0-d1c99e24cbcb?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "66807418",
"date_amm": "1996-12-06",
"type_amm": "Procédure de reconnaissance mutuelle",
"numero_ue": null,
"substance": "LÉNOGRASTIM",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "poudre et solvant pour solution injectable pour perfusion",
"voies_administration": "intraveineuse;sous-cutanée",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about lenograstim.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.